Regardless ,the die is set.. Regardless of what is written, or by whom, tomorrow ONC will be doing the now anticipated oral presentation.
Acullly not ONC,but the study team.
Onc management will do a coda, Monday Am, premarket.
speculations?
im not expecting any business development news. THAT, was made clear last CC.
We do need & Im hopefully expecting results exceeding the original phase 2. Certainly needs to be better than, what was presented most recently.
Apparently the 50% improvement, over TAxol alone, is subject to interpretation.( sarcasm intended).
Striping away, 25 years of history & mutiple trials.....
mangament knows full well a B.D. Deal is needed to give any sustained SP increase.
Since, we know that won't be announced Monday, The SP will react to
1. The significance of the oral & up-to-date MBc data.
2. The take away from KOL webinar.
both need to be solid.
Have a great weekend all.
PS
What we don't know is the actual pharma interest?
We als don't know ONCs stratagy.
The written stuff says. " looking towards a phase 3 license deal"
That, could regrettably extend things out until the Pancreatic results.I believe that is expected 2H of this year.
Meaning, anytime between now & Dec 31.
As a long term shareholder. Assuming a quick deal could be done at xxx$ PS.
or wait until a more significant deal with Roche,
That process would bother a lot of people. However in the long run, would produce a significant amount of value.
Again, I'll be looking for clarity on Monday.